article thumbnail

Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

TechCrunch

Neuroglee Therapeutics , a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. million to develop digital therapeutics for neurodegenerative diseases. Neuroglee gets $2.3 Venture investing in elder tech.

article thumbnail

The growing power of digital healthcare: 6 trends to watch in 2022

TechCrunch

But startups will continue to lead the way in innovation with the use of AI, IoT and data analytics, especially with data becoming the central currency of healthcare. Digital therapeutics will rewrite the future of healthcare. Healthcare deals were hot in the first nine months in 2021. They brought in a total of $21.3

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Neuroglee gets $2.3 million to develop digital therapeutics for neurodegenerative diseases

TechCrunch

Neuroglee , a Singapore-based health tech startup, wants to help with a digital therapeutic platform created to treat patients in the early stages of the disease. one of Japan’s largest pharmaceutical companies, and Kuldeep Singh Rajput, the founder and chief executive officer of predictive healthcare startup Biofourmis.

article thumbnail

6 questions investors should ask when evaluating psychedelic biotech companies

TechCrunch

As a venture firm that invests in psychedelics, we receive hundreds of pitches every month from founders developing psychedelic therapeutics. Our fund has invested more than $15 million in companies developing psychedelic therapeutics. Greg Kubin is a partner at PsyMed Ventures and co-host of Business Trip.

article thumbnail

11 investors predict a colorful, if difficult, future for psychedelic startups

TechCrunch

But that’s not to say the path to commercialization and wider adoption is closed to psychedelic startups and investors at the moment. Does this make psychedelics startups that aren’t developing any drugs more attractive to investors than those involved in drug development? This is very much a Darwinian model being played out.

startup 99
article thumbnail

Atommerce wants to scale its mental health platform with $16.7M funding

TechCrunch

Atommerce , a Korean startup that helps users connect with mental health professionals via a mobile app MiNDCAFE, plans to scale its mental health service with a $16.7 The Seoul-based startup offers a virtual therapy program and a mental health benefits solution for employers.

health 83
article thumbnail

BrainCheck brings in another $10M to detect, manage cognitive impairment

TechCrunch

As the world’s population ages, more is being learned about brain health as startups leverage technology to find a way to slow down cognitive impairment. This startup just raised $8 million to help busy doctors assess the cognitive health of 50 million seniors.